In this episode, Mindy, Ryan, and Jen discuss a few recent newsworthy items including recent approvals from the House Energy and Commerce Subcommittee on Health and Phase 3 clinical trial results for oral semaglutide to treat obesity.

Podcast Tags: healthcare, healthcare news, health plans, life sciences, health policy, public health, Medicare, drug prices, PBMs, 340B, obesity

Source Links: 

• A key House panel approved a slew of health policies. Here's a look at 4 of them 
• Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial 
• Anti-obesity medications are set to skyrocket this year. But how will we afford them? 
• What Could New Anti-Obesity Drugs Mean for Medicare? 

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC. 

Mindy McGrath, Healthcare Industry Advisor and Head of Public Health Sector 

Mindy.McGrath@vynamic.com

Ryan Hummel, Executive and Head of Provider Sector 

Ryan.Hummel@vynamic.com

Jen Burke, Healthcare Industry Strategist 

Jen.Burke@vynamic.com